000272837 001__ 272837
000272837 005__ 20241029085443.0
000272837 0247_ $$2doi$$a10.1007/s00702-024-02797-9
000272837 0247_ $$2pmid$$apmid:38916622
000272837 0247_ $$2pmc$$apmc:PMC11489162
000272837 0247_ $$2ISSN$$a0375-9245
000272837 0247_ $$2ISSN$$a0022-3026
000272837 0247_ $$2ISSN$$a0300-9564
000272837 0247_ $$2ISSN$$a1435-1463
000272837 0247_ $$2altmetric$$aaltmetric:164903076
000272837 037__ $$aDZNE-2024-01255
000272837 041__ $$aEnglish
000272837 082__ $$a610
000272837 1001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b0$$eFirst author$$udzne
000272837 245__ $$aThe why and how of the SynNerGe criteria of Parkinson´s disease.
000272837 260__ $$aWien [u.a.]$$bSpringer$$c2024
000272837 3367_ $$2DRIVER$$aarticle
000272837 3367_ $$2DataCite$$aOutput Types/Journal article
000272837 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729588935_23954$$xReview Article
000272837 3367_ $$2BibTeX$$aARTICLE
000272837 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272837 3367_ $$00$$2EndNote$$aJournal Article
000272837 520__ $$aIn pursuit of early therapeutic interventions for Parkinson's disease, the proposed SynNeurGe classification system integrates α-synuclein pathology (S), neurodegeneration evidence (N), and pathogenic gene variants (G). This approach aims to address the disease's complexity and biological diversity. It suggests categorizing patients based on the presence or absence of α-synuclein pathology in tissues or cerebrospinal fluid, neurodegeneration indicators from specific imaging techniques, and identification of pathogenic gene variants associated with Parkinson's disease. The proposed system emphasizes the future need for precision medicine and aims to facilitate both basic and clinical research toward disease-modifying therapies. However, the authors stress that initial implementation should be confined to research settings, considering ethical implications and current limitations. Prospective validation of these criteria is deemed necessary to ensure their efficacy and ethical application in clinical practice.
000272837 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272837 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272837 650_7 $$2Other$$aBiological definition
000272837 650_7 $$2Other$$aGenetics
000272837 650_7 $$2Other$$aNeurodegeneration
000272837 650_7 $$2Other$$aParkinson’s disease
000272837 650_7 $$2Other$$aSynuclein
000272837 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000272837 650_2 $$2MeSH$$aHumans
000272837 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000272837 650_2 $$2MeSH$$aParkinson Disease: genetics
000272837 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000272837 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000272837 7001_ $$aLang, Anthony E$$b1
000272837 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-024-02797-9$$gVol. 131, no. 10, p. 1149 - 1154$$n10$$p1149 - 1154$$tJournal of neural transmission$$v131$$x0375-9245$$y2024
000272837 8564_ $$uhttps://pub.dzne.de/record/272837/files/DZNE-2024-01255.pdf$$yOpenAccess
000272837 8564_ $$uhttps://pub.dzne.de/record/272837/files/DZNE-2024-01255.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272837 909CO $$ooai:pub.dzne.de:272837$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272837 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000272837 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272837 9141_ $$y2024
000272837 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000272837 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272837 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000272837 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000272837 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272837 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000272837 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x0
000272837 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000272837 980__ $$ajournal
000272837 980__ $$aVDB
000272837 980__ $$aUNRESTRICTED
000272837 980__ $$aI:(DE-2719)1110002
000272837 980__ $$aI:(DE-2719)1111015
000272837 9801_ $$aFullTexts